MIAMI BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced the voluntary prepayment of $10.0 million of its outstanding term loan debt using cash on hand, following the successful completion of its offering of 3,634,000 shares of common stock, which generated net proceeds, after estimated expenses, of approximately $13.8 million. The Company noted that with this financing and assum ...

MIAMI BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the closing of its previously announced underwritten public offering of 3,160,000 shares of common stock. In addition, the underwriter has exercised in full its option to purchase an additional 474,000 shares of common stock. The proceeds from the offering, after estimated expenses, are estimated to be approx ...

MIAMI BEACH, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the pricing of its previously announced underwritten public offering of 3,160,000 shares of common stock. AirSculpt has agreed to sell the shares to the underwriter at a price of $3.80 per share, for proceeds to the Company, before expenses, of $12.0 million. AirSculpt has also granted the underwriter a 30-da ...

MIAMI BEACH, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) (“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the launch of an underwritten public offering of 3,160,000 shares of its common stock. The underwriter will also have a 30-day option to purchase up to 474,000 additional shares of common stock. All of the shares of common stock in the offering are being sold by the Company. Vesey Street Capital Partners, L. ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Financial Performance - Revenue for Q1 2025 was $39.371 million, a decrease of 17% compared to $47.620 million in Q1 2024[18] - The net loss for Q1 2025 was $2.847 million, compared to a net income of $6.029 million in Q1 2024, reflecting a significant decline in profitability[18] - Adjusted net loss for the three months ended March 31, 2025, was $1.1 million, compared to an adjusted net income of $1.9 million for the same period in 2024[123] - For the three months ended March 31, 2025, the company generated approximately $39.4 million in revenue, a decline of approximately 17% compared to $47.6 million for the same period in 2024[101] - The company reported a net loss of $2.847 million for Q1 2025, compared to a net income of $6.029 million in Q1 2024[112] Expenses and Costs - Operating expenses increased to $40.960 million in Q1 2025, up from $36.608 million in Q1 2024, primarily due to a rise in selling, general, and administrative expenses[18] - Selling, general and administrative expenses increased by $6.0 million, or 38.2%, for the three months ended March 31, 2025, with selling expenses decreasing to approximately $9.6 million from $11.2 million[126][127] - Cost of service decreased by $2.1 million, or 11.6%, compared to the same period in 2024, with cost of service as a percentage of revenue at 40.5% for 2025 and 37.9% for 2024[125] - The company incurred rent expenses of $1.8 million for medical office suites in Q1 2025, compared to $1.5 million in Q1 2024[76] Cash and Liquidity - Cash and cash equivalents decreased to $5.553 million as of March 31, 2025, down from $8.235 million at the end of 2024[15] - The Company maintains cash balances that may exceed the amount covered by the Federal Deposit Insurance Corporation, with no losses experienced in such accounts[37] - The company is required to maintain minimum liquidity of $3.0 million as of March 31, 2025, increasing to $7.5 million thereafter[147] Assets and Liabilities - Total assets as of March 31, 2025, were $203.260 million, a decrease from $209.996 million at the end of 2024[15] - Total liabilities decreased to $125.927 million as of March 31, 2025, compared to $130.706 million at the end of 2024[15] - As of March 31, 2025, total debt, net was $68.5 million, down from $69.7 million as of December 31, 2024[74] Tax and Regulatory - The effective tax rate for the three months ended March 31, 2025, was approximately 11.4%, significantly lower than the 36.4% rate for the same period in 2024[59] - The effective tax rate for the three months ended March 31, 2025, was 11.4%, compared to 36.4% for the same period in 2024[131] Operational Metrics - The company performed 3,076 cases in Q1 2025, down from 3,746 cases in Q1 2024, representing a case growth decline of 17.9%[104] - Same-center case growth declined by 24.3% in Q1 2025, with revenue per case slightly increasing by 0.5% to $12,777[107] - The number of facilities increased to 32 in Q1 2025 from 27 in Q1 2024, and the total number of procedure rooms rose to 67 from 57[104] Debt and Financing - The Company voluntarily prepaid $10.0 million of the principal balance of term loans under the Credit Agreement on September 29, 2023[69] - The Company entered into a credit agreement on November 7, 2022, with an original aggregate principal amount of term loans of $85.0 million and a revolving loan facility of up to $5.0 million[144] - As of March 31, 2025, the total indebtedness of the company was $73.5 million, including $5.0 million drawn on the revolving credit facility[143] Equity and Compensation - The Company granted 888,301 restricted stock units (RSUs) in Q1 2025, up from 411,456 RSUs in Q1 2024[79] - The Company recorded equity-based compensation expense of $1.2 million for Q1 2025, compared to a reversal of $(6.8) million in Q1 2024[83] Strategic Initiatives - The company has implemented a cost reduction program expected to eliminate approximately $3.0 million in annual overhead costs and contracted expenses[102] - The company is focusing on new product innovation, including a pilot skin tightening procedure as a standalone offering[105] - The company plans to launch expanded consumer financing offerings across all centers by the end of Q2 2025[105] Miscellaneous - There were no changes in internal control over financial reporting that materially affected the company during the quarter ended March 31, 2025[157] - No relevant financial performance or user data was provided in the documents[169] - There are no future outlook or performance guidance details available in the content[170] - No information regarding new products or technology development was found in the documents[171] - There are no mentions of market expansion or acquisitions in the provided content[172] - No new strategies or initiatives were outlined in the documents[172]

AirSculpt (AIRS) Q1 2025 Earnings Call May 02, 2025 08:00 AM ET Company Participants Allison Malkin - PartnerYogi Jashnani - CEO & DirectorDennis Dean - CFOJoshua Raskin - Partner - Managed Care & ProvidersMorgan McCarthy - VP - Equity Research Conference Call Participants Sam Eiber - Vice President and Medical Technology AnalystKorinne Wolfmeyer - Vice President & Senior Equity Research Analyst - Beauty and Wellness Operator Greetings and welcome to the AirSculpt Technologies Inc. First Quarter twenty twen ...

AirSculpt (AIRS) Q1 2025 Earnings Call May 02, 2025 08:00 AM ET Company Participants Allison Malkin - PartnerYogi Jashnani - CEO & DirectorDennis Dean - CFOJoshua Raskin - Partner - Managed Care & ProvidersMorgan McCarthy - VP - Equity Research Conference Call Participants Sam Eiber - Vice President and Medical Technology AnalystKorinne Wolfmeyer - Vice President & Senior Equity Research Analyst - Beauty and Wellness Operator Greetings and welcome to the AirSculpt Technologies Inc. First Quarter twenty twen ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $39.4 million, a decline of 17.3% from Q1 2024, with adjusted EBITDA at $3.8 million and a margin of 9.5%, down from $7.3 million and 15.4% in the prior year [6][23][24] - Same store revenue decreased approximately 24% year-over-year, consistent with previous trends [7][20] - Average revenue per case was $12,799, slightly higher than the first quarter of 2024 [20][23] Business Line Data and Key Metrics Changes - Cases declined by 17.9% to 3,070, primarily due to lower consumer spending and reduced marketing efforts [20][21] - The percentage of patients using financing for procedures was 44%, down from 50% in the previous quarter [21] Market Data and Key Metrics Changes - The company operates in a challenging macroeconomic environment, impacting consumer spending and case volumes [5][18] - Despite the decline, there was an improvement in lead generation and case performance from February to April 2025 [7][20] Company Strategy and Development Direction - The company is focused on stabilizing performance and laying the foundation for long-term growth through cost discipline, marketing efficiency, and operational rigor [5][6] - Strategic priorities include reallocating marketing spend to effective channels, optimizing sales processes, and introducing new services to meet consumer demand [14][15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation efforts and the potential for future growth, despite current economic pressures [5][19] - The guidance for fiscal 2025 anticipates revenue between $160 million and $170 million, with adjusted EBITDA between $16 million and $18 million, reflecting a cautious outlook due to uncertain consumer behavior [17][25] Other Important Information - The company is monitoring inflationary pressures and consumer sentiment, which could impact discretionary spending on procedures [18] - Cost of service decreased by $2.1 million compared to the prior year, but as a percentage of revenue increased to 40.5% due to fixed costs [21][22] Q&A Session Summary Question: Specific cost savings and sustainability - Management noted significant cost savings from workforce changes, targeting $3 million in savings for the year [28] Question: Potential EBITDA margins and case growth - Management expects EBITDA margins to approach historical levels of around 30% as same store revenue improves [30] Question: Momentum in cases and seasonal patterns - Management confirmed improvements in cases were both seasonal and due to strategic initiatives, with a target for same store sales growth by year-end [31] Question: Underlying assumptions in guidance - Guidance incorporates a range of scenarios, with the low end accounting for further moderation in consumer spending [47][48] Question: Financing options and their impact - Financing options are expected to roll out by the end of Q2, which management believes will help increase case volumes [52][54]

Financial Performance - First quarter 2025 revenue was $39.4 million, a decline of 17.3% from $47.6 million in the first quarter of fiscal year 2024[6] - The net loss for the quarter was $2.8 million, compared to a net income of $6.0 million in the first quarter of fiscal year 2024[6] - Adjusted EBITDA for the first quarter was $3.8 million, down from $7.3 million in the first quarter of fiscal year 2024[6] - Adjusted net loss for Q1 2025 was $1,108,000, while adjusted net income for Q1 2024 was $1,880,000[31] - Basic and diluted Adjusted Net Income per share for Q1 2025 was $(0.02), compared to $0.03 in Q1 2024[31] Case Volume and Revenue per Case - Case volume decreased by 17.9% to 3,076 in the first quarter of 2025, down from 3,746 in the same period last year[6] - For the three months ended March 31, 2025, the company reported 2,837 cases, a decrease of 24.3% compared to 3,746 cases in the same period of 2024[22] - The average revenue per case increased slightly to $12,799 in the first quarter of 2025 from $12,712 in the first quarter of 2024[20] - Revenue per case increased by 0.5% to $12,777 from $12,712 year-over-year[22] Cash Flow and Guidance - The company generated $0.9 million in operating cash flow for the first quarter of 2025, compared to $3.4 million for the same period in 2024[5] - As of March 31, 2025, the company had $5.6 million in cash and cash equivalents, down from $8.2 million at the end of 2023[20] - The company projects full year 2025 revenue guidance of approximately $160 to $170 million[6] - Adjusted EBITDA guidance for the full year 2025 is expected to be approximately $16 to $18 million[6] Operational Costs and Expenses - The company incurred $1,239,000 in equity-based compensation in Q1 2025, compared to a reversal of $(6,781,000) in Q1 2024[29] - Restructuring and related severance costs were $863,000 in Q1 2025, up from $296,000 in Q1 2024[29] - The company reported an interest expense of $1,625,000 in Q1 2025, slightly up from $1,532,000 in Q1 2024[29] Facilities and Services - The company maintained 27 facilities and 57 total procedure rooms in both Q1 2025 and Q1 2024[22] - The company is piloting a standalone skin tightening service, which has seen increasing interest from consumers[3]